BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Obsidian Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Obsidian Therapeutics\, Inc.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06060613-2650@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:OBX-115: Phase 1/2 readout est. (NCT06060613)
DESCRIPTION:OBX-115\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Efficacy of OBX-115 in Advanced Solid Tumors\nEstimated primary comp
 letion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obx-115#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06060613
URL:https://assetmemo.bio/drug/obx-115#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
